Tariff Clarity And Sustainability Will Unlock Cellulose Potential

Key Takeaways

• Global demand for sustainable cellulose-based products and favorable trade policies are driving revenue and margin growth, with industry shifts benefiting North American producers.
  
• Strategic investments in automation, biomaterials, and cost efficiency are set to reduce production costs, diversify revenue, and improve long-term cash flow.
  
• Operational disruptions, market softness, cost inflation, and execution risks threaten margins, revenue stability, and the company's ability to successfully commercialize new initiatives and achieve financial targets.

Catalysts

Manufactures and sells cellulose specialty products in the United States, China, Europe, Japan, rest of Asia, Canada, Latin America, and internationally.

• The stabilization of trade policies and resolution of tariff uncertainties, especially in China and the US, are reversing previous export disruptions; this is anticipated to drive a rebound in cellulose specialties volumes and improved pricing, supporting topline revenue growth and enhanced EBITDA margins going forward.
  
• Accelerated growth in global demand for cellulose-based products-driven by consumer and corporate shifts toward sustainable, bio-based materials and tightening climate policy-is expanding addressable markets for Rayonier Advanced Materials; this underpins expectations for both revenue and margin expansion as specialty cellulose gains share across diverse end markets.
  
• Strategic investments in process automation, operational efficiencies, and cost reduction-already underway-are expected to lower unit production costs meaningfully by 2026, setting the stage for sustainable improvements in net margins and cash flow conversion.
  
• Successful execution of high-return biomaterial projects (bioethanol, biofuels, tall oil) leveraging existing infrastructure is projected to add significant incremental EBITDA (with equity returns of 7x–10x on capital invested), further diversifying the company's revenue base and meaningfully increasing long-term free cash flow.
  
• Industry consolidation, heightened supply chain localization, and a strong balance sheet position Rayonier Advanced Materials to capture market share from exiting or disadvantaged competitors, particularly as environmental regulations and tariffs provide tailwinds to North American producers; this dynamic is set to support higher capacity utilization rates and stronger pricing power, positively impacting both revenue and margins.

Rayonier Advanced Materials Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Rayonier Advanced Materials's revenue will grow by 2.2% annually over the next 3 years.
• Analysts are not forecasting that Rayonier Advanced Materials will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Rayonier Advanced Materials's profit margin will increase from -29.4% to the average US Chemicals industry of 9.1% in 3 years.
• If Rayonier Advanced Materials's profit margin were to converge on the industry average, you could expect earnings to reach $148.2 million (and earnings per share of $2.12) by about August 2028, up from $-447.3 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 4.0x on those 2028 earnings, up from -0.8x today. This future PE is lower than the current PE for the US Chemicals industry at 26.1x.
• Analysts expect the number of shares outstanding to grow by 1.65% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 11.96%, as per the Simply Wall St company report.

Rayonier Advanced Materials Future Earnings Per Share Growth

Risks

• Despite management's assertion that 2025 headwinds are largely "onetime," recurring operational disruptions-including labor strikes, outages, and production challenges-have been a consistent feature and may reflect deeper structural issues with the company's aging asset base and manufacturing processes, posing ongoing risks to future production volumes and EBITDA margins.
  
• Persistent softness in the paperboard and high-yield pulp segments, as well as ongoing exposure to volatile global pulp pricing and oversupply conditions (especially in China), could continue to weigh on overall revenues and segment-level profitability, undermining full recovery and target margin expansion.
  
• The company's ambitious biomaterials initiatives and capital deployment plans rely heavily on successful execution of new projects and commercialization in established but highly competitive markets; failure to meet commercialization timelines or secure favorable offtake agreements could delay or reduce projected earnings and free cash flow, especially if market entrants intensify competition or prices soften.
  
• RYAM's high reliance on a few core segments and customers, and the plan to divest noncore assets for deleveraging, could expose the company to revenue volatility and increase financial risk if divestitures fetch lower-than-expected valuations or if execution is delayed, ultimately straining net leverage targets and future capital flexibility.
  
• Ongoing inflation in wage, energy, and raw materials costs, combined with the need for continued capital expenditures on process automation and facility upgrades, may structurally compress margins and free cash flow, especially if input cost increases outpace gains from efficiency initiatives or if industry pricing power abates.

Valuation

• The analysts have a consensus price target of $6.0 for Rayonier Advanced Materials based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.6 billion, earnings will come to $148.2 million, and it would be trading on a PE ratio of 4.0x, assuming you use a discount rate of 12.0%.
  
• Given the current share price of $5.05, the analyst price target of $6.0 is 15.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.